Experience the wave of excitement sweeping through the realm of synthetic peptide! From Novo Nordisk's monumental $6 billion expansion in peptides to Merck's groundbreaking advancements in macrocyclic peptides, and the dynamic collaboration between Genentech and Peptidream, the power of peptides in revolutionizing drug development is undeniable.

But the journey doesn't stop there. As the demand for complex peptides skyrockets and the need for large-scale manufacturing intensifies, the Peptide Process Development & CMC Summit emerges as the beacon guiding you through this exhilarating landscape.

Join us for an immersive experience where innovation meets practicality:

• Master the art of synthesizing intricate peptide-drug conjugates, cyclic, and macrocyclic peptides, propelling your next-generation developments to new heights.
• Unleash the potential of traditional synthesis and purification techniques, maximizing efficiency and ensuring top-notch quality production.
• Embark on a voyage of exploration into alternative synthesis processes—biological, solid phase, liquid phase, hybrid—empowering you to select the most efficient approach with an eye toward the future.
• Gain invaluable insights into control strategies and CMC requirements, navigating regulatory waters with confidence while maintaining unwavering commitment to quality.
• Scale up your peptide manufacturing operations, catering to the diverse needs of clinical development and patient populations across a spectrum of diseases.

The ONLY industry-led summit focusing on the synthetic peptide upstream and downstream process development and CMC for seamless technology transfer.

Join us this July where we unite Analytical, Process Development and CMC experts. This exclusive event stands as the sole summit dedicated to synthetic peptide upstream and downstream process development across the next generation of peptides – covering conjugates to cyclic peptides. Join experts from Amgen, Lilly, Merck, and Novartis to revolutionize your approach and embrace the future of peptide-driven drug development with confidence and quality in mind.